MedTrace Logo

Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

NCT05736991 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-02-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting the grade 3 tumors based on the novel grading system in clinical stage stage I lung adenocarcinoma based on a multicenter prospective cohort.

Conditions

Interventions

DIAGNOSTIC_TEST

PET/CT-based Radiomics Signature

Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

Sponsors & Collaborators

  • Ningbo No.2 Hospital

    collaborator OTHER

  • Zunyi Medical College

    collaborator OTHER

  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05736991 on ClinicalTrials.gov